These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21092287)

  • 21. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
    J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation.
    Brearley C; Jaber A; Bertolino M; Priestley A; Seiberling M
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):307-18. PubMed ID: 17595888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
    García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
    BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
    Dahari H; Affonso de Araujo ES; Haagmans BL; Layden TJ; Cotler SJ; Barone AA; Neumann AU
    J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics of pegylated interferons: what is misleading?
    Caliceti P
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The interferons: pharmacology, mechanism of action, tolerance and side effects].
    Arnaud P
    Rev Med Interne; 2002 Nov; 23 Suppl 4():449s-458s. PubMed ID: 12481400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.
    Gupta SK; Pittenger AL; Swan SK; Marbury TC; Tobillo E; Batra V; Sack M; Glue P; Jacobs S; Affrime M
    J Clin Pharmacol; 2002 Oct; 42(10):1109-15. PubMed ID: 12362925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
    Talal AH; Ribeiro RM; Powers KA; Grace M; Cullen C; Hussain M; Markatou M; Perelson AS
    Hepatology; 2006 May; 43(5):943-53. PubMed ID: 16761329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.
    Hadziyannis SJ; Papatheodoridis GV
    Expert Opin Pharmacother; 2003 Apr; 4(4):541-51. PubMed ID: 12667117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.
    Daud AI; Xu C; Hwu WJ; Urbas P; Andrews S; Papadopoulos NE; Floren LC; Yver A; Deconti RC; Sondak VK
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):657-66. PubMed ID: 20509027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.
    Jeon S; Juhn JH; Han S; Lee J; Hong T; Paek J; Yim DS
    J Transl Med; 2013 Oct; 11():240. PubMed ID: 24088361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2a.
    Saito T; Iida S; Kawanishi T
    Drug Metab Pharmacokinet; 2012; 27(6):614-20. PubMed ID: 22785255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.